The bigger dog barks to its owner / slave....and you are then beaten.
First and foremost, Atossa Genetics has developed a tool (MASCT) that can save the lives of countless women through the early detection of breast cancer. The tool and procedure, which is non-invasive, trumps the radiation and needle biopsy tests, along with mammograms. Kudos to Atossa! Second, this has the potential to make investors a little money.
Sentiment: Strong Buy
This is going to blow up by weeks end.
Who says "smart minds" on the street are not buying. Small-cap, biotech companies are usually binary event trades, and therefore AFFY is a speculative trade. This is not a trade based on eps beats, forward growth, divys, revenue forecasts...plain and simple..will Omontys return? Why 1.17? It's trading @ what most people believe is their cash value. And I don't believe it's a opportunity of a lifetime, it's just a trade with the potential for great returns. Omontys return= PPS Increase above cash value due to potential milestone/royalty$
This is the conclusion I have reached after reviewing the available data and information regarding the adverse and fatal reactions. For anyone that has done their DD, this is pretty clear to see. The facts are the facts, and they are right under your nose.